HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Joint Juice

This article was originally published in The Tan Sheet

Executive Summary

National rollout for glucosamine joint health beverage underway, San Francisco-based firm says. Previously available only in West Coast retailers, Joint Juice will hit Safeway stores in California, Oregon, Washington, Alaska, Arizona and Colorado by May, with full U.S. distribution expected by end of 2003, firm says. Joint Juice contains 1,500 mg glucosamine per serving and is available in lemonade, tropical and orange-tangerine flavors; beverage comes in ready-to-drink bottles or liquid drink mixes, retailing for $1.99 and $1.29, respectively (1"The Tan Sheet" March 19, p. 11)...

You may also be interested in...



Joint Juice

San Francisco-based company introduces 1,500 mg glucosamine beverage to retailers at Natural Products Expo West in Anaheim, Calif. March 9-11. Joint Juice comes in a ready-to-drink bottle or a liquid drink pouch, which must be mixed with 10 oz. cold water, according to labeling. The company is beginning a public relations campaign which will highlight the benefits of glucosamine and the convenience of a beverage form. Joint Juice currently is available on the firm's Web site, jointjuice.com, or at Costco, Albertsons and independent retailers in northern California. The ready-to-drink bottle and liquid drink mix retail for $1.99 and $1.29, respectively

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel